MapLight Therapeutics, Inc. ($MPLT) announced an update on their ongoing clinical study. MapLight Therapeutics Advances Mid-Stage Trial for ...

In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who ...

Tv Therapeutics (VTVT) announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & ...

The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure medication over 2 years ...

“The launch of this trial enables us to evaluate the safety and efficacy of cadisegliatin over the course of one year in people with insulin-dependent type 2 diabetes, allowing for extended ...